Nephrogen
New accelerator entry · 2022-08-19 · the record
In their words
Nephrogen is a Stanford biotech spin-out developing curative genetic medicines for kidney and pancreatic diseases. Kidney disease alone affects 1 in 7 Americans, and neither indication has any approved gene-based therapies. Nephrogen's underlying platform combines AI and high-throughput screening to engineer safer, more efficient, and less expensive gene delivery vehicles for reaching the kidney and pancreas, and has attracted non-dilutive funding from seven major pharmaceutical companies including Merck KGaA, Novartis, and Bristol Myers Squibb.
What the record says
- One of 65 companies held here in Healthcare › Therapeutics.
No investor is drawn from a Form D — the form states how many invested and never who. The one investor on this graph is named because a batch has exactly one.
The full profile
Source Check, INVEST, RECRUIT and Press Requests on Nephrogen
- Source Check — verify what Nephrogen states, against the registers that hold it.
- INVEST — size up this company on the figures its record states.
- RECRUIT — see who is already on the team.
- Press Requests — connect with Nephrogen for a story.
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist NephrogenYou get an alert in MentionFox the next time this company shows up.
Is this you?
If you're behind Nephrogen: acceptance into a YC batch is one of the few weeks a young company gets looked up by people who matter — investors, other founders, press. FoxPlug turns the commits, deploys, and releases you're already making into that story automatically, so anyone who looks finds something current. FoxChat puts a guide on your own site so the people YC's own page just sent you don't read one line and leave.
Sourced from the company's Y Combinator directory entry.